Fennec Pharmaceuticals (FENC) Competitors $4.48 +0.25 (+5.91%) (As of 11/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FENC vs. DNA, PRME, MGTX, TSHA, VALN, FDMT, VYGR, CCCC, ENGN, and JSPRShould you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Ginkgo Bioworks (DNA), Prime Medicine (PRME), MeiraGTx (MGTX), Taysha Gene Therapies (TSHA), Valneva (VALN), 4D Molecular Therapeutics (FDMT), Voyager Therapeutics (VYGR), C4 Therapeutics (CCCC), enGene (ENGN), and Jasper Therapeutics (JSPR). These companies are all part of the "biological products, except diagnostic" industry. Fennec Pharmaceuticals vs. Ginkgo Bioworks Prime Medicine MeiraGTx Taysha Gene Therapies Valneva 4D Molecular Therapeutics Voyager Therapeutics C4 Therapeutics enGene Jasper Therapeutics Fennec Pharmaceuticals (NASDAQ:FENC) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Does the MarketBeat Community believe in FENC or DNA? Fennec Pharmaceuticals received 173 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 66.11% of users gave Fennec Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformFennec PharmaceuticalsOutperform Votes19766.11% Underperform Votes10133.89% Ginkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Do analysts prefer FENC or DNA? Fennec Pharmaceuticals currently has a consensus price target of $13.67, indicating a potential upside of 205.06%. Ginkgo Bioworks has a consensus price target of $4.16, indicating a potential downside of 51.63%. Given Fennec Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Fennec Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Ginkgo Bioworks 3 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Is FENC or DNA more profitable? Fennec Pharmaceuticals has a net margin of -2.30% compared to Ginkgo Bioworks' net margin of -298.78%. Fennec Pharmaceuticals' return on equity of -53.38% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Fennec Pharmaceuticals-2.30% -53.38% -2.08% Ginkgo Bioworks -298.78%-55.91%-33.48% Do institutionals and insiders hold more shares of FENC or DNA? 55.5% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 11.0% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation and earnings, FENC or DNA? Fennec Pharmaceuticals has higher earnings, but lower revenue than Ginkgo Bioworks. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFennec Pharmaceuticals$48.89M2.51-$16.05M-$0.10-44.80Ginkgo Bioworks$251.46M1.90-$892.87M-$13.08-0.66 Which has more risk & volatility, FENC or DNA? Fennec Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Does the media refer more to FENC or DNA? In the previous week, Ginkgo Bioworks had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 15 mentions for Ginkgo Bioworks and 14 mentions for Fennec Pharmaceuticals. Ginkgo Bioworks' average media sentiment score of 0.27 beat Fennec Pharmaceuticals' score of -0.08 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fennec Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryFennec Pharmaceuticals beats Ginkgo Bioworks on 12 of the 18 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Fennec Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FENC vs. The Competition Export to ExcelMetricFennec PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.88M$3.12B$5.16B$8.94BDividend YieldN/A1.77%5.04%4.03%P/E Ratio-44.8029.57107.9916.24Price / Sales2.51312.801,298.8092.29Price / CashN/A179.8139.4036.42Price / Book-23.584.446.425.98Net Income-$16.05M-$42.42M$115.02M$225.08M7 Day Performance-9.49%-2.07%-0.76%0.37%1 Month Performance1.36%8.52%4.85%5.73%1 Year Performance-43.07%41.83%41.38%31.75% Fennec Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FENCFennec Pharmaceuticals1.8402 of 5 stars$4.48+5.9%$13.67+205.1%-44.2%$122.88M$48.89M-44.80N/AAnalyst RevisionDNAGinkgo Bioworks1.0244 of 5 stars$8.60+2.5%$4.16-51.6%N/A$477.99M$251.46M-0.661,218Short Interest ↓News CoverageHigh Trading VolumePRMEPrime Medicine3.1305 of 5 stars$3.96-8.3%$13.25+234.6%-36.5%$475.32MN/A-1.93234Analyst ForecastNews CoverageGap DownMGTXMeiraGTx4.6001 of 5 stars$7.04+5.7%$22.50+219.6%+38.5%$456.90M$14.02M-5.03300Positive NewsGap UpTSHATaysha Gene Therapies2.4651 of 5 stars$2.21-7.5%$6.38+188.5%+58.8%$452.92M$15.45M-11.05180Analyst ForecastNews CoverageGap UpHigh Trading VolumeVALNValneva2.87 of 5 stars$5.07+5.8%$18.50+264.9%-65.3%$411.94M$165.52M-39.00700Gap DownFDMT4D Molecular Therapeutics2.5014 of 5 stars$7.71-2.0%$47.14+511.5%-28.8%$400.69M$20.72M-3.35201Upcoming EarningsShort Interest ↓News CoveragePositive NewsVYGRVoyager Therapeutics4.5649 of 5 stars$6.69-2.0%$17.43+160.5%+7.6%$364.83M$143.77M9.42100Analyst DowngradeNews CoverageGap UpCCCCC4 Therapeutics2.031 of 5 stars$5.13-6.9%$11.20+118.3%+220.3%$362.13M$20.76M-3.02150Short Interest ↓ENGNenGene3.1578 of 5 stars$8.12-4.7%$33.67+314.6%+1.4%$359.07MN/A0.0031JSPRJasper Therapeutics2.722 of 5 stars$22.80-4.5%$74.86+228.3%+245.7%$344.28MN/A-4.8120Upcoming Earnings Related Companies and Tools Related Companies Ginkgo Bioworks Alternatives Prime Medicine Alternatives MeiraGTx Alternatives Taysha Gene Therapies Alternatives Valneva Alternatives 4D Molecular Therapeutics Alternatives Voyager Therapeutics Alternatives C4 Therapeutics Alternatives enGene Alternatives Jasper Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FENC) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
